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        Introduction 
  Leukocyte migration from blood to tissues plays a central role in 
infl  ammatory and immune responses. This migration of leukocytes 
occurs in a multistep process that involves cognate interactions be-
tween circulating cells and the vascular wall (  Ley et al., 2007  ). The 
fi  rst interactive step mediated by selectins results in rolling of the 
leukocytes along the vascular endothelium. Exposure of leukocytes 
to chemokines released and presented by infl  amed tissues triggers 
the activation of leukocyte integrins. Activated integrins therefore 
engage ligands on vascular endothelial cells to mediate fi  rm adhe-
sion of leukocytes to the vessel wall and their movement toward in-
terendothelial junctions ( Schenkel et al., 2004 ). These steps precede 
the diapedesis of the leukocytes from the vascular lumen into the 
surrounding tissue by migrating through junctions between endo-
thelial cells, and in some cases, by migrating through the endothe-
lial cell body (  Vestweber, 2007  ). 
  Several endothelial adhesion molecules act as leukocyte 
integrin ligands and are involved in leukocyte migration. Leu-
kocyte fi  rm adhesion is mediated by the interaction of endothe-
lial vascular cell adhesion molecule-1 (VCAM-1) with the 
integrin     4    1   (VLA-4) and of intercellular adhesion molecule-1 
and -2 (ICAM-1 and ICAM-2) with the integrins     L    2   (LFA-1) 
and     M    2   (Mac-1). In addition, the members of the junctional 
adhesion molecule (JAM) family expressed by endothelial cells 
have been proposed to constitute other leukocyte integrin li-
gands (  Bazzoni, 2003  ;   Ebnet et al., 2004  ;   Weber et al., 2007  ). 
The JAM protein family consists of three members: JAM-A, 
JAM-B, and JAM-C, which are Ig superfamily molecules with 
two extracellular Ig domains and a short cytoplasmic tail ending 
with a type II PDZ-binding motif. The prototypical member of 
the family, JAM-A, was initially described as a tight junction 
molecule expressed by endothelial and epithelial cells and in-
volved in monocyte migration in vivo (  Martin-Padura et al., 1998  ). 
J
unctional adhesion molecules (JAMs) are endothe-
lial and epithelial adhesion molecules involved in 
the recruitment of circulating leukocytes to inﬂ  am-
matory sites. We show here that JAM-L, a protein related 
to the JAM family, is restricted to leukocytes and pro-
motes their adhesion to endothelial cells. Cis dimeriza-
tion of JAM-L is required to engage in heterophilic 
interactions with its cognate counter-receptor CAR (cox-
sackie and adenovirus receptor). Interestingly, JAM-L 
expressed on neutrophils binds CAR independently of 
integrin activation. However, on resting monocytes and 
T lymphocytes, which express the integrin VLA-4, JAM-L 
molecules engage in complexes with VLA-4 and mainly 
accumulate in their monomeric form. Integrin activation 
is required for the dissociation of JAM-L  –  VLA-4 com-
plexes and the accumulation of functional JAM-L dimers, 
which indicates that the leukocyte integrin VLA-4 con-
trols JAM-L function in cis by controlling its dimerization 
state. This provides a mechanism through which VLA-4 
and JAM-L functions are coordinately regulated, allow-
ing JAM-L to strengthen integrin-dependent adhesion of 
leukocytes to endothelial cells.
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  Figure 1.       JAM-L expression is restricted to neutrophils, monocytes, and memory T cells.   (A) Neutrophils, monocytes, and T lymphocytes freshly isolated 
from human peripheral blood and HBMECs stained with anti  –  JAM-L and analyzed by ﬂ  ow cytometry. Gray areas represent staining with secondary anti-
body alone. (B) Freshly isolated human T lymphocytes stained were with antibodies directed against the molecules indicated, ﬁ  xed, and analyzed by ﬂ  ow 
cytometry. Lines demarcate the threshold for positive staining for both markers.     1161 JAM-L FUNCTION IS REGULATED BY VLA-4   • Luissint et al. 
JAM-A binds the leukocyte integrin LFA-1 and regulates the 
adhesion and transmigration of lymphocytes in vitro (  Ostermann 
et al., 2002  ). In addition, JAM-A is expressed by leukocytes, 
platelets, and erythrocytes. The two other members of the fam-
ily, JAM-B and JAM-C, were described as endothelial adhesion 
molecules highly expressed by high endothelial venules and 
lymphatic endothelial cells in lymphoid organs, respectively 
(  Cunningham et al., 2000  ;   Palmeri et al., 2000  ;   Arrate et al., 
2001  ;   Aurrand-Lions et al., 2001  ). Endothelial JAM-C can pro-
mote lymphocyte migration through homophilic interactions 
(  Johnson-Leger et al., 2002  ) and is involved in neutrophil trans-
endothelial migration by interacting with Mac-1 (  Chavakis 
et al., 2004  ). In addition, JAM-C has been shown to be expressed 
on human leukocytes and to interact with JAM-B (  Arrate et al., 
2001  ;   Liang et al., 2002  ), an interaction that facilitates the bind-
ing of endothelial JAM-B to the integrin VLA-4 expressed on 
lymphocytes (  Cunningham et al., 2002  ). Therefore, JAM family 
members seem to facilitate leukocyte transmigration by inter-
acting in trans with the leukocyte     2 integrins LFA-1 and Mac-1, 
as well as with the     1 integrin VLA-4, through their extracellu-
lar domains, and by engaging in heterophilic interactions in trans 
among JAM family members. 
  Additional Ig superfamily members structurally related to 
the JAMs and potentially involved in leukocyte  –  endothelial cell 
interactions have been identifi  ed: the coxsackie and adenovirus 
receptor (CAR), endothelial cell-selective adhesion molecule 
(ESAM), JAM-4, and JAM-L. CAR, ESAM, and JAM-4 mole-
cules are expressed at endothelial and epithelial junctions and 
share a similar overall organization with JAMs: two Ig-like do-
mains, a single transmembrane domain, and a longer cytoplasmic 
tail that ends in a canonical type I PDZ domain – binding sequence. 
JAM-L, however, is expressed on leukocytes, and its cytoplas-
mic tail does not possess a PDZ-binding motif (  Moog-Lutz et al., 
2003  ). ESAM is involved in the extravasation of neutrophils but 
not that of lymphocytes (  Wegmann et al., 2006  ), and JAM-L 
can participate in neutrophil migration across epithelial tight 
junctions by interacting with CAR (  Zen et al., 2005  ). The mo-
lecular mechanisms by which JAM-L and other JAM-related 
molecules may facilitate the transmigration of specifi  c leuko-
cyte populations are still largely unresolved. 
  In this study, we found that JAM-L  –  mediated leukocyte 
adhesion to endothelial cells is regulated in cis by VLA-4 integ-
rin activation. We provide evidence that JAM-L expressed on 
neutrophils can directly interact with its cognate counter-receptor 
CAR independently of integrin activation. However, on resting 
monocytes and T lymphocytes, which, unlike neutrophils, ex-
press the integrin VLA-4, JAM-L constitutively associates with 
VLA-4. This interaction prevents the cis dimerization of JAM-L, 
which is required for the functional recognition of CAR. Integ-
rin activation is thus necessary to dissociate JAM-L  –  VLA-4 
complexes and to promote the formation of JAM-L dimers. Our 
results demonstrate that the leukocyte integrin VLA-4 unex-
pectedly regulates JAM-L function in cis by controlling its di-
merization state; they strongly suggest that VLA-4 integrin and 
JAM-L functions are coordinately regulated, allowing JAM-L 
to contribute to the strengthening of the integrin-dependent ad-
hesion of leukocytes to endothelial cells. 
  Results 
  JAM-L expression is restricted to 
neutrophils, monocytes, 
and memory T cells 
  We previously identifi  ed JAM-L as a novel protein with homol-
ogy to members of the JAM family. JAM-L mRNA was up-
regulated in myeloid leukemia cells induced to differentiate 
through the granulocytic and monocytic pathways, and was ex-
pressed in normal hematopoietic cells, including neutrophils, 
monocytes, and lymphocytes (  Moog-Lutz et al., 2003  ). Using 
anti  –  human JAM-L antibodies, we investigated JAM-L expres-
sion in freshly isolated human leukocytes and in cultured endo-
thelial or epithelial cells. Consistent with the presence of 
JAM-L mRNA in leukocytes, JAM-L protein expression was 
detected at the surface of neutrophils, monocytes, and, to a 
lesser extent, human T lymphocytes (  Fig. 1 A  ). However, JAM-L 
expression was not detected on human CD34 
+   hematopoietic 
stem cells and progenitors freshly isolated from umbilical cord 
blood (unpublished data). In addition, neither JAM-L protein 
(  Fig. 1 A  ) nor mRNA expression (not depicted) were detected 
in a human bone marrow microvascular endothelial cell line; 
nor was it detected in endothelial or epithelial cells of different 
origins (primary cultures of human umbilical vein endothelial 
cells, saphenous vein endothelial cells, and dermal microvas-
cular endothelial cells, as well as in the brain microvessel en-
dothelial cell line hCMEC/D3 or the epithelial cells lines T84 
and Caco-2; not depicted), which strongly suggests that, unlike 
any other JAMs and related molecules, human JAM-L expres-
sion is restricted to mature leukocytes. 
  Characterization of JAM-L expression among T lympho-
cyte subpopulations showed that JAM-L is expressed on both 
CD4 
+   and CD8 
+   T cells (    40% and 30%, respectively;   Fig. 1 B  ) 
with a memory cell phenotype. Staining with antibodies to 
CD45RA and CD45RO isoforms of the leukocyte common 
antigen, which functionally identify distinct   “  naive  ”   and   “  mem-
ory  ”   T cell subsets, respectively, indicates that 90% of the 
JAM-L – positive  cells  express  CD45RO 
+  , whereas only 30% ex-
press CD45RA. In addition, 8  –  15% express CD25 
+   and HLA-
DR 
+  , two markers of the activated T cells (  Fig. 1 B  ). JAM-L was 
therefore mainly expressed on a large subpopulation of memory 
T cells (30  –  35% of CD45RO 
+   T cells). Interestingly, JAM-L 
expression was predominant on   l-  selectin and CC-chemokine 
receptor 7  –  negative T cells (CD62L 
      and CCR7 
     ) that charac-
terize a subpopulation of effector memory T cells, which pref-
erentially migrate to peripheral tissues, as opposed to CD62L 
+  
and CCR7 
+   central memory T cells, which preferentially mi-
grate to lymph nodes (  Lefrancois, 2006  ). In addition, JAM-L 
was expressed on a fraction of T cells expressing the integrin 
   4   7 (associated with gut homing) and of T cells expressing 
the cutaneous leukocyte antigen (CLA) and CC-chemokine 
receptor 4 (CCR4; associated with skin homing). 
 Collectively,  these  fi  ndings indicate that JAM-L is selec-
tively expressed by the fi  rst effectors of both innate and adapta-
tive immune responses and strongly suggest that it may directly 
participate in the traffi  cking of memory T lymphocytes to non-
lymphoid organs. JCB • VOLUME 183 • NUMBER 6 • 2008  1162
ing and cytokine-stimulated human bone marrow endothelial 
cells (HBMECs;   Moog-Lutz et al., 2003  ). Interestingly, an in-
teraction between JAM-L and epithelial CAR has been de-
scribed supporting the transepithelial migration of neutrophils 
(  Zen et al., 2005  ). By expressing JAM-L in the human chronic 
  Cis dimerization of JAM-L is required to 
engage in heterophilic interactions 
with CAR 
  We previously found that exogenous expression of JAM-L in 
myeloid cells resulted in enhanced cell adhesion to both rest-
  Figure 2.       Cis-dimerization of JAM-L is required for its interaction with CAR.   (A) K562 cells were double transfected with vectors encoding JAM-L  –  HA 
and JAM-L  –  GFP or with JAM-L  –  HA and ICAM-1  –  GFP. After lysis, immunoprecipitations (IP) were performed with anti-HA or anti-GFP, as indicated. Immune 
complexes were subjected to immunoblotting (IB) with anti-HA or anti-GFP. Arrows indicate the electrophoretic mobility of JAM-L  –  HA, JAM-L  –  GFP, or 
ICAM-1  –  GFP. The bracket indicates an IgG heavy chain. (B) K562 cells were transfected with vectors encoding wild-type (JAM-L  –  WT, gray) or mutated 
(JAM-L  –  K54D, black) JAM-L coupled to HA, or empty vector (white) as control. Cells were then loaded with CMFDA, and adhesion assays were performed 
on immobilized CAR-Fc or CD25-Fc proteins in RPMI medium. Cells were incubated for 40 min at 37  °  C, adherent cells were lysed, and ﬂ  uorescence inten-
sity was measured. The basal adhesion of K562 empty vector cells on CD25-Fc protein was 8% of the total number of incubated cells. Results are means   ±   SD 
(  n   = 4) of a representative three independent experiments (***, P   <   0.001). (C) K562 cells expressing JAM-L  –  WT  –  HA or JAM-L  –  K54D  –  HA were labeled 
using anti  –  JAM-L, ﬁ  xed, and analyzed by ﬂ  ow cytometry (bold black lines). Gray areas represent staining with the secondary antibody alone. (D) K562 
cells expressing JAM-L  –  WT  –  HA or JAM-L  –  K54D  –  HA were lysed, then immunoprecipitations and immunoblots were performed with anti-HA. Two exposure 
times are shown for each blot. Arrows indicate the electrophoretic mobility of monomers and dimers of JAM-L  –  HA. Black lines indicate that intervening 
lanes have been spliced out. Numbers next to gel blots indicate molecular mass markers in kD. (E) K562 cells were transfected with JAM-L  –  WT  –  HA or 
JAM-L  –  K54D  –  HA and treated or not treated with BS 
3   before cell lysis and Western blot analysis with anti-HA. (F) The proportion of dimeric and monomeric 
forms of JAM-L  –  WT  –  HA (gray) or JAM-L  –  K54D  –  HA (black) in E was calculated using ImageJ.     1163 JAM-L FUNCTION IS REGULATED BY VLA-4   • Luissint et al. 
distal Ig-like domain (  Kostrewa et al., 2001  ;   Prota et al., 2003  ). 
Moreover, Cis dimerization of JAM-A was shown to be required 
for homophilic interaction and function in intercellular junction 
assembly (  Bazzoni et al., 2000  ;   Liu et al., 2000  ;   Mandell et al., 
2004  ). As this dimerization motif is conserved between JAM 
members and JAM-L, we questioned whether JAM-L forms homo-
dimers in cis. For this purpose, K562 cells were cotransfected 
with two constructs of JAM-L bearing different tags, JAM-L-
GFP and JAM-L-HA, or cotransfected with JAM-L-HA and 
ICAM-1  –  GFP, as a control. As shown in   Fig. 2 A  , JAM-L  –  GFP 
was coimmunoprecipitated with JAM-L  –  HA, and vice versa. 
myeloid leukemia cell line K562, which lacks endogenous 
JAM-L, we also observed that these cells adhere specifi  cally 
to CAR (Fig. S1, available at http://www.jcb.org/cgi/content/
full/jcb.200805061/DC1).  Additionally,  JAM-L – mediated  ad-
hesion of K562 cells to HBMECs was prevented by the addi-
tion of soluble CAR protein (CAR-Fc chimeric molecules), 
which is consistent with the idea that JAM-L can promote 
leukocyte adhesion to endothelial cells by interacting with 
CAR (Fig. S1). 
  Crystal structures have revealed that JAM-A molecules 
form homodimers in cis via a dimerization motif in the membrane 
  Figure 3.       In monocytic cells, JAM-L function 
requires integrin activation in cis to enhance 
cell adhesion.   (A) K562 cells transfected with 
an empty vector or a vector encoding JAM-L 
(left) or U937/pMT  –  JAM-L  –  HA cells untreated 
or treated with Zn 
2+   to induce JAM-L  –  HA ex-
pression (right) were labeled using anti  –  JAM-L, 
then ﬁ  xed and analyzed by ﬂ  ow cytometry. 
(B) K562 cells were transfected with JAM-L  –
  GFP (gray) or GFP alone (white). Cells were 
preincubated for 5 min at 37  °  C in PBS with 
EDTA or Mn 
2+  , and adhesion to HBMECs was 
assayed in the same buffer for 30 min at 37  °  C. 
The number of adherent GFP-positive cells was 
determined by FACS analysis. The basal adhe-
sion level was 2% of the total number of incu-
bated cells (**, P   <   0.01). (C and D) U937 
cells stably transfected with pMT  –  JAM-L  –  HA 
were untreated (white) or treated (gray) with 
Zn 
2+   to induce JAM-L expression and then 
loaded with CMFDA. (C) U937 cells were pre-
incubated for 5 min at 37  °  C in PBS with EDTA 
or Mn 
2+  . Adhesion to HBMECs was assayed in 
the same buffers for 30 min at 37  °  C. The basal 
adhesion level was 5% (***, P   <   0.001). 
(D) U937 cells were left untreated (NT) or stimu-
lated for 5 min at 37  °  C with 100 ng/ml SDF-1     
in PBS Ca 
     /Mg 
     . Cells were then subjected 
to adhesion to HBMECs in the same buffers 
for 30 min at 37  °  C. The basal adhesion level 
was 5% (**, P   <   0.01). (E) FACS analysis of 
U937/pMT  –  JAM-L  –  HA transfected with Talin-
F23  –  GFP (bold black lines) or with GFP alone 
(broken lines). Cells were stained with 9EG7 or 
MEM-148 antibodies, which recognize active 
    1 or     2 integrin subunits, respectively, in PBS 
(no cation, top) or PBS with Mn 
2+   (manganese, 
bottom). Only GFP-positives cells were ana-
lyzed by ﬂ  ow cytometry. Gray areas represent 
staining proﬁ  les with secondary antibodies 
alone. (F) U937/pMT  –  JAM-L  –  HA cells were 
untreated (white) or treated (gray) with Zn 
2+   
and transfected with Talin-F23  –  GFP or GFP for 
8 h. Adhesion to HBMECs was assayed in PBS 
Ca 
     /Mg 
      for 30 min at 37  °  C. The number of 
adherent GFP-positive cells was determined by 
FACS analysis. The basal adhesion level was 
6% (***, P   <   0.001). Results in B, C, D, and 
F are means   ±   SD (  n   = 3) of a representative 
three independent experiments.     JCB • VOLUME 183 • NUMBER 6 • 2008  1164
membrane by fl  ow cytometry (  Fig. 2 C  ). Because JAM-A was 
shown to form SDS-resistant dimers (  Prota et al., 2003  ), we 
analyzed the ability of the K54D point mutation to inhibit 
JAM-L dimerization by immunoprecipitation and immuno-
blotting. After immunoprecipitation with an anti-HA antibody, 
a monomeric form of     48 kD was detected in immuno-
complexes from K562 cells transfected with JAM-L  –  HA or 
JAM-L 
K54D  – HA. In addition, when further exposed, minor bands 
of     100 kD corresponding to dimeric forms of JAM-L were 
detected from K562 cells expressing JAM-L but were barely 
visible in the case of JAM-L 
K54D   ( Fig.  2  D ).  Furthermore,  us-
ing Bis(sulfosuccinimidyl)suberate (BS 
3  ), a noncleavable, 
membrane-impermeable cross-linking agent, before cell lysis 
and analysis by Western blotting, we observed that 80  –  90% 
of the JAM-L molecules present in K562 cells were stabilized 
in a dimeric form, whereas this proportion was decreased to 
30  –  35% by the K54D substitution. This, therefore, clearly 
shows that most of the JAM-L molecules form dimers at the 
However, no coimmunoprecipitation between JAM-L  –  HA and 
ICAM-1  –  GFP was observed, therefore specifi  cally demonstrat-
ing that JAM-L is able to homodimerize. 
  To assess whether JAM-L homodimer formation was re-
quired for JAM-L function, we used a JAM-L construct with a 
substitution of the lysine 54 by aspartic acid in the dimeriza-
tion motif (JAM-L 
K54D  ). As CAR binding to JAM-L is medi-
ated by an interaction between the membrane-distal Ig domain 
of CAR and the membrane-proximal Ig domain of JAM-L 
(  Zen et al., 2005  ), this mutation is unlikely to directly perturb 
the interaction. We have previously shown that this mutation 
abolished the ability of JAM-L to promote leukocyte adhesion 
to an endothelial monolayer when expressed in the monocytic 
U937 cell line (  Moog-Lutz et al., 2003  ). Using K562 cells 
transfected with either JAM-L  –  HA or JAM-L 
K54D  – HA,  we 
show here that this point mutation also abolished JAM-L  –
  mediated adhesion to immobilized CAR-Fc (  Fig. 2 B  ), al-
though both proteins could be detected at the cell plasma 
  Figure 4.       The dependence of JAM-L  –  mediated adhesion of human leukocytes on integrin activation is cell type speciﬁ  c.   Freshly isolated human neutro-
phils (A) or monocytes (C) were loaded with CMFDA, incubated with 20   μ  g/ml of soluble JAM-L  –  Fc or CD25-Fc, or no soluble proteins (    ), as indicated, 
for 30 min at 37  °  C, then added to wells containing immobilized chimeric CD25-Fc, ICAM-1-Fc, or CAR-Fc proteins for 40 min at 37  °  C in PBS Ca 
     /Mg 
      
and with EDTA. Adherent cells were lysed and ﬂ  uorescence intensity was measured. Results are expressed as the amount of ﬂ  uorescence released from 
adherent cells, normalized relative to the adhesion of the cells to CD25-Fc, to which 7% of neutrophils or 14% of monocytes adhered. Results are means   ±   
SD (  n   = 4) of a representative four independent experiments (***, P   <   0.001). (B) K562 cells were transfected with vectors encoding JAM-L  –  GFP (gray) 
or GFP alone (white), and added to wells containing immobilized chimeric CD25-Fc or CAR-Fc proteins for 40 min at 37  °  C in PBS Ca 
     /Mg 
      with EDTA. 
The number of adherent GFP-positive cells was determined by FACS analysis. The basal adhesion level was 7%. Results are means   ±   SD (  n   = 3) of a 
representative three independent experiments (**, P   <   0.01). (D) U937 cells stably transfected with pMT  –  JAM-L  –  HA were untreated (white) or treated 
(gray) with Zn 
2+   to induce JAM-L expression. Cells were loaded with CMFDA and added to wells containing immobilized chimeric CD25-Fc or CAR-Fc 
proteins for 40 min at 37  °  C in PBS Ca 
     /Mg 
      with EDTA. The basal adhesion level was 26%. Results are means   ±   SD (  n   = 3) of a representative three 
independent experiments.     1165 JAM-L FUNCTION IS REGULATED BY VLA-4   • Luissint et al. 
  Figure 5.       JAM-L associates with VLA-4.   (A) U937/pMT  –  JAM-L  –  HA cells were untreated (    ) or treated (+) with Zn 
2+   to induce JAM-L  –  HA expres-
sion. After lysis, immunoprecipitations (IP) were performed with mouse IgG1 isotype antibodies directed against HA,     4,     1, or VSV-g epitope tag 
as a negative control. Immune complexes were immunoblotted (IB) with anti-HA or anti-    1 antibodies. Black lines indicate that intervening lanes 
have been spliced out. Numbers next to gel blots indicate molecular mass markers in kD. (B) Freshly isolated T lymphocytes were plated on poly-
  L  -lysine and stimulated or not stimulated for 10 min at 37  °  C with 100 ng/ml SDF-1     in PBS Ca 
     /Mg 
      before ﬁ  xation. Cells were triple stained 
for JAM-L (green),     4 subunit (red), and actin (blue), then analyzed by confocal microscopy. (right) Merged images (overlay) of the same ﬁ  elds. 
Bars, 10   μ  M.     JCB • VOLUME 183 • NUMBER 6 • 2008  1166
  Figure 6.       JAM-L function is regulated in cis by the activation state of VLA-4 integrin.   (A) U937/pMT  –  JAM-L  –  HA cells were incubated with antibodies 
against     4 subunit (P4C2) or CD71 for 30 min at 37  °  C. Cells were washed and surface stained with 9EG7 antibody at 4  °  C for 30 min in the absence 
of cation (bold black lines). In addition, U937 cells were incubated with 9EG7 antibody in the presence of Mn 
2+   (gray broken lines) as a positive control 1167 JAM-L FUNCTION IS REGULATED BY VLA-4   • Luissint et al. 
for integrin activation or in the absence of cation (thin black lines) to indicate the basal level of integrin activation. Cells were labeled with R-phycoerythrin  – 
conjugated secondary antibodies, then ﬁ  xed and analyzed by ﬂ  ow cytometry. Gray areas represent staining with the secondary antibody alone. 
(B) U937/pMT  –  JAM-L  –  HA cells were untreated (white) or treated (gray) with Zn 
2+   to induce JAM-L  –  HA expression. Cells were labeled with CMFDA and 
incubated with either anti-    4 (P4C2) or anti-CD71, and adhesion to HBMECs prewashed with PBS Ca 
     /Mg 
      was assayed for 30 min at 37  °  C. Adherent 
cells were lysed and ﬂ  uorescence intensity was measured. Basal adhesion was 2% of the total number of incubated cells. Results are means   ±   SD (  n   = 3) 
of a representative three independent experiments (**, P   <   0.01). (C and D) K562 cells were transfected with vectors encoding JAM-L  –  GFP (gray) or GFP 
(white). Also, double transfectants were generated with human     4 subunit (+). K562 cells were added to wells containing immobilized VCAM1-Fc proteins 
(C) or CAR-Fc proteins (D) in PBS without cations or in the presence of Mn 
2+   for 40 min at 37  °  C. The number of adherent GFP-positive cells was determined 
by FACS analysis. Results are expressed as the quantity of adherent cells, normalized relative to the basal adhesion of K562/JAM-L and     4-negative cells. 
The basal adhesion level on CAR-Fc and VCAM1-Fc was 8% and 2% of the total number of incubated cells, respectively. Results are means   ±   SD (  n   = 4) 
of a representative three independent experiments (**, P   <   0.01). (E) FACS analysis of K562 cells transfected with vectors encoding JAM-L-GFP alone,     4 
subunit alone, or double transfected with both constructs. Lines demarcate the threshold for positive staining for both markers.     
 
membrane and that the K54D mutation affects the stabilization of 
JAM-L dimers. These results provide the fi  rst evidence of the 
importance of dimerization of JAM-related proteins to engage 
in heterophilic interactions. 
  JAM-L  –  mediated adhesion of human 
monocytes or T lymphocytes, but not that 
of neutrophils, requires integrin activation 
  In characterizing the JAM-L  –  dependent adhesion of leukocytes 
to endothelial cells, we routinely performed adhesion in RPMI 
medium containing the cations Ca 
2+ ,  Mg 
2+ ,  and  Mn 
2+ .  The  de-
pendence of integrin function on divalent cations is well estab-
lished (  Luo et al., 2007  ); therefore, we examined the possible 
role of integrins in JAM-L  –  mediated adhesion by analyzing the 
dependence of K562 cells or U937 cells (expressing or not ex-
pressing JAM-L to a similar extent;   Fig. 3 A  ) on divalent cations 
for adhesion to endothelial cells using PBS buffer containing 
EDTA (which inhibits integrin function) or Mn 
2+   (which acti-
vates integrins). Intriguingly, JAM-L  –  mediated adhesion of 
K562 cells to HBMECs was observed both in PBS buffer con-
taining EDTA or Mn 
2+   (  Fig. 3 B  ), whereas JAM-L  –  mediated 
adhesion of U937 cells, which express zinc-inducible JAM-L  –
  HA, was strictly dependent on the presence of Mn 
2+   ( Fig.  3  C ), 
which suggests the involvement of an integrin in JAM-L  –  medi-
ated function in U937 cells. 
 To  confi  rm this hypothesis, an adhesion assay of U937 
cells was performed in PBS in the presence or absence of the 
chemokine stromal cell-derived factor-1 (SDF-1   /CXCL12),  a 
well known   “  inside-out  ”   activating factor of integrins (  Kim 
et al., 2003  ). As shown in   Fig. 3 D  , JAM-L  –  mediated adhesion 
of U937 cells to HBMECs was detected only in the presence of 
SDF-1    . We then questioned whether this effect was caused by 
the activation of monocytic or endothelial integrins. For that 
purpose, U937 cells that conditionally express JAM-L  –  HA 
were further transiently transfected with either GFP alone (con-
trol) or with the head domain of talin coupled to GFP (Talin 
F23  –  GFP) to directly activate integrins in those cells through an 
interaction with their      subunit cytoplasmic tails (  Tadokoro 
et al., 2003  ). As expected, the expression of Talin F23  –  GFP in 
U937 cells led to the activation of both    1  and    2  integrins,  as 
assessed by FACS analysis using antibodies directed against ac-
tivated      integrins (  Fig. 3 E  ). An adhesion assay of these U937 
cells was then performed in PBS (  Fig. 3 F  ). JAM-L  –  mediated 
adhesion of U937 cells to HBMECs was observed with Talin 
F23  –  GFP  –  expressing cells but not with control cells. These re-
sults demonstrate that the activation of a leukocyte integrin 
(not endothelial integrin) is required to reveal JAM-L function 
in U937 cells. This effect was not caused by any increase in    1 
or     2 integrin expression, nor integrin activation caused by 
JAM-L expression (unpublished data). 
  Because previous work indicated that neutrophil adhesion 
to CAR can occur in a cation-independent manner (  Zen et al., 
2005  ), we then analyzed the contribution of the endogenous 
JAM-L to the adhesion of freshly isolated neutrophils and mono-
cytes to immobilized CAR in PBS containing EDTA. We observed 
that the adhesion of neutrophils to CAR was abolished in the pres-
ence of soluble JAM-L – Fc, whereas the addition of soluble CD25-Fc 
at the same concentration as a control had no effect (  Fig. 4 A  ). 
These results indicate that JAM-L can mediate the adhesion of 
human neutrophils to CAR independently of integrin activation, 
as observed with K562 cells, in which JAM-L expression 
promoted their cation-independent adhesion to CAR (  Fig. 4 B  ). 
However, the addition of soluble JAM-L  –  Fc did not affect the ad-
hesion of freshly isolated monocytes to CAR (  Fig. 4 C  ) or of 
T lymphocytes (not depicted), which indicates that JAM-L does 
not support their adhesion in the absence of integrin activation. 
Interestingly, these results are similar to what was observed in the 
monocytic U937 cell line, in which JAM-L expression did not 
promote adhesion to CAR in PBS containing EDTA (  Fig. 4 D  ). 
  Collectively, these results provide the unexpected evi-
dence that JAM-L function is regulated in cis by leukocyte inte-
grins, and that this effect is selectively observed in individual 
leukocyte subpopulations, which suggests that the integrins re-
sponsible for JAM-L regulation are expressed by monocytes 
and T lymphocytes but not by freshly isolated neutrophils or 
K562 cells. 
  JAM-L associates with VLA-4 integrin 
 VLA-4  (   4    1  ) is one of the main integrins involved in leuko-
cyte interactions with endothelial cells, and is expressed in 
T lymphocytes and monocytes but not in K562 cells or neu-
trophils. As VLA-4 expression correlates with the regulation 
in cis of JAM-L function, we investigated whether JAM-L 
could interact with VLA-4  .   Immunoprecipitations were per-
formed from cell lysates of the U937 cells that conditionally 
express JAM-L  –  HA. JAM-L  –  HA was detected both in     4   and 
    1   precipitates (  Fig. 5 A  ). We therefore determined the cell-
surface distribution of endogenous VLA-4 and JAM-L on 
T lymphocytes by confocal immuno  fl  uorescence  analysis 
(  Fig. 5 B  ). When plated on poly-  l  -lysine in PBS buffer, cells 
remained predominantly round, and both VLA-4 and JAM-L 
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  VLA-4 integrin controls the dimerization 
state of JAM-L 
  Because JAM-L dimerization is required to engage in hetero-
philic interactions with CAR (  Fig. 2  ), we then investigated 
whether the interaction between JAM-L and VLA-4 controlled 
the dimerization state of JAM-L using K562 cells that we trans-
fected with JAM-L  –  HA alone or together with    4  ( Fig.  7  A ). 
We observed that in K562 cells expressing JAM-L-HA alone, SDS-
resistant dimers of JAM-L are constitutively present, even in the 
absence of SDF-1     treatment (  Fig. 7 B  , middle), which is consis-
tent with our observation that JAM-L expression can promote the 
adhesion of K562 cells independently of integrin activation. 
However, when cotransfected with     4-GFP, a constitutive in-
teraction between     4 and the monomeric form of JAM-L  –  HA 
was detected, as previously observed in U937 cells (  Fig. 5 A  ). 
Indeed,     4-GFP was detected in JAM-L  –  HA immunoprecipi-
tates (  Fig. 7 B  , top), and, conversely, JAM-L – HA was detected in 
    4-GFP immunoprecipitates (  Fig. 7 C  , top). In addition, this in-
teraction was accompanied by a dramatic decrease in the amount 
of dimeric JAM-L ( Fig. 7 B , middle), which is consistent with our 
observation that coexpression of both JAM-L and VLA-4 prevents 
JAM-L  –  mediated adhesion of K562 cells to CAR (  Fig. 6 D  ). 
  However, upon integrin activation by cell treatment with 
SDF-1    , the interaction between VLA-4 and JAM-L monomers 
was largely decreased (  Fig. 7, B and C  , top), accompanied by 
the formation of JAM-L dimers (  Fig. 7  , middle). This is consistent 
with the observation of a restored JAM-L  –  mediated adhesion to 
CAR in the presence of integrin-activating factor (  Fig. 6 D  ). 
These results demonstrate that the interaction between JAM-L 
and VLA-4 blocks JAM-L function by preventing the formation 
or stabilization of JAM-L dimers. Integrin activation leads to the 
dissociation of JAM-L  –  VLA-4 complexes, which is required 
for JAM-L dimerization and recognition of CAR. 
  To further address how VLA-4 expression affects the di-
merization state of JAM-L, we analyzed the proportion of JAM-L 
dimers formed in K562 cells in the presence or absence of resting 
or activated VLA-4 integrins using BS 
3   before cell lysis and anal-
ysis by Western blotting. As shown in   Fig. 7 (D and E)  , in the ab-
sence of   4 expression, 80 – 90% of the JAM-L molecules present 
in K562 cells were stabilized by BS 
3   treatment in a dimeric form. 
This proportion was not affected by SDF-1     stimulation. How-
ever, when coexpressed with   4, the proportion of JAM-L dimers 
formed was affected, as most of the JAM-L molecules were now 
accumulated in their monomeric form (65  –  70%). Integrin activa-
tion upon SDF-1     treatment then restored the accumulation of 
most of the JAM-L molecules in a dimeric form (75 – 85%). These 
results provide evidence that the inactive form of VLA-4 controls 
JAM-L function by preventing the formation of JAM-L dimers at 
the plasma membrane. However, it is interesting to note that BS 
3  
treatment did not increase the proportion of     4 associated with 
JAM-L (unpublished data), which suggests that the integrin may 
not be in close contact with JAM-L or may be indirectly associ-
ated with JAM-L. 
  All together, our results demonstrate that VLA-4 regulates 
JAM-L function in cis by controlling its dimerization state. This 
fi  nding suggests a mechanism through which VLA-4 integrin 
and JAM-L functions are coordinately regulated, allowing JAM-L 
largely colocalized. Interestingly, after SDF-1     treatment 
for 10 min, T lymphocytes spread out and, while VLA-4 
remained associated with polymerized cortical actin, JAM-L 
molecules accumulated at one pole of the cells, where they 
formed a cap structure. In addition, upon SDF-1     treatment, 
    30% of the cells acquired a polarized morphology, with 
the formation of a large actin-rich lamellipodia at the leading 
edge and a spherical membrane protrusion budding at the 
rear, called a   “  uropod.  ”   In these polarized cells, both VLA-4 
and JAM-L were present in the uropod; in addition, a 
fraction of VLA-4, but not of JAM-L, was present in the 
mid-hind region. These results indicate that JAM-L appears 
to colocalize with VLA-4 integrin in the absence of activating 
stimulus, whereas the two proteins partially overlapped upon 
SDF-1     treatment. 
  JAM-L function is regulated in cis by 
VLA-4 integrin 
  To assess whether the activation of VLA-4 was suffi  cient to pro-
mote JAM-L function, the adhesion to HBMECs of U937 cells that 
conditionally express JAM-L – HA was assessed in PBS in the pres-
ence of P4C2, an antibody against     4.   The addition of P4C2 anti-
body to U937 cells induced VLA-4 activation, as assessed by FACS 
analysis using antibodies directed against an activated     1   integrin 
subunit (  Fig. 6 A  ). As a control, addition of an isotype-matched ir-
relevant antibody (anti-CD71, which binds to U937 cells) failed to 
activate VLA-4. Interestingly, addition of P4C2 antibody revealed 
JAM-L  –  mediated adhesion of U937 cells expressing JAM-L to 
resting HBMECs in the absence of Mn 
2+   (  Fig. 6 B  ). Similar results 
were obtained using HP2/1, another antibody with VLA-4  –  activat-
ing activity (unpublished data;   McGilvray et al., 1997  ). These re-
sults therefore strongly suggest that the activation of VLA-4 is 
required to unmask JAM-L function in cellular adhesion. 
  To extend and further validate the fi  nding that VLA-4 in-
teraction with JAM-L controls the JAM-L  –  mediated adhesion 
of leukocytes to endothelial cells, we used the K562 cells, as 
these cells do not express     4   but express     1 .  Transfection  of 
K562 cells with     4   restored functional VLA-4 heterodimers, en-
abling the cation-dependent adhesion of K562 cells to immobi-
lized VCAM-1 (  Fig. 6 C  ), which is in line with previous studies 
(  Munoz et al., 1996  ). We then observed that, although K562 
cells expressing JAM-L alone adhere to immobilized CAR-Fc 
independently of any integrin-activating factor, as expected 
(  Fig. 6 D  ), the adhesion of K562 cells expressing both JAM-L 
and VLA-4 to immobilized CAR-Fc was not observed in the ab-
sence of cation (  Fig. 6 D  ). The JAM-L  –  mediated adhesion of 
K562 cells expressing JAM-L and VLA-4 to CAR was therefore 
strictly dependent on the presence of Mn 
2+   (  Fig. 6 D  ). As a con-
trol, we show that the expression of JAM-L was not affected by 
    4   expression, as assessed by fl  ow cytometry (  Fig. 6 E  ). Con-
versely, JAM-L expression does not signifi   cantly affect    4 
(or     1) expression, nor the ability of VLA-4 integrin to bind 
VCAM-1 in both K562 (  Fig. 6, C and E  ) and U937 cells (not 
depicted). All together, these results demonstrate that, when co-
expressed with JAM-L, VLA-4 integrin activation is required to 
allow the functional interaction between JAM-L and CAR. 
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genesis, and vascular pathologies (  Ebnet et al., 2004  ;   Weber 
et al., 2007 ). JAM-L is related to the JAM family and has particu-
lar structural and functional properties. JAM-L does not possess 
the canonical PDZ-binding motif present at the C terminus of 
the other JAM molecules and related members, which is essen-
tial for their function in the organization of tight junctions and 
cell polarity in epithelial cells (  Ebnet et al., 2004  ). Unlike the 
other JAM family members, we did not fi  nd JAM-L expressed 
in various endothelial or epithelial cells. We present evidence 
here that JAM-L is expressed on neutrophils and monocytes, 
which are the fi  rst line of host defense against infection by bac-
terial pathogens. These cells are mobilized within hours to sites 
of infl  ammation, where they mediate bactericidal activity. In ad-
dition, we show that JAM-L is predominantly expressed on ef-
fector memory T cells, negative for the expression of   l-  selectin 
and the CC-chemokine receptor 7. This observation is of partic-
ular interest because this subset of memory T cells is known to 
migrate in nonlymphoid and mucosal sites, where they can im-
mediately confront the invading pathogens (  Lefrancois, 2006  ). 
Moreover, JAM-L is found on T cells expressing specifi  c hom-
ing molecules involved in traffi  cking to the skin and the intestinal 
mucosa. This cellular distribution strongly suggests a major role 
to strengthen the integrin-dependent adhesion of leukocytes to 
endothelial cells. 
  Discussion 
  Leukocyte migration from the blood to tissues involves a series 
of molecular interactions between leukocyte and endothelial 
cell adhesion molecules. It is established that the activity of 
these adhesion molecules must be coordinated in time and space 
for proper leukocyte diapedesis (  Ley et al., 2007  ). Our results 
here demonstrate an original regulation in cis of the leukocyte 
adhesion molecule JAM-L function by the integrin VLA-4. 
Integrin activation is required to promote JAM-L  –  mediated leu-
kocyte adhesion to endothelial cells, which suggests that these 
molecules are coordinately regulated to optimally support the 
adhesion and extravasation of leukocytes. 
  JAMs and related molecules are known to play multiple 
functions. Because of their expression on endothelial and epi-
thelial cells, leukocytes, and platelets, JAMs contribute to adhe-
sive interactions with circulating leukocytes and platelets, tight 
junction formation in epithelial and endothelial cells during the 
establishment of cell polarity, growth factor  –  mediated angio-
  Figure 7.       VLA-4 integrin controls the dimerization state of JAM-L.   (A  –  C) K562 cells were transfected with JAM-L  –  HA or double transfected with JAM-L  –  HA 
and the human     4 subunit. Cells were then untreated (    ) or treated with SDF-1     (100 ng/ml for 5 min) before lysis. (A) Whole cell extracts were analyzed 
by immunoblotting with anti-HA and anti-GFP to show that similar amounts of JAM-L and     4 were expressed in these different conditions. Arrows indicate 
the electrophoretic mobility of     4-GFP and of monomers and dimers of JAM-L  –  HA. Lysates were immunoprecipitated (IP; B) with anti-HA or with anti-GFP 
(C), and immune complexes were separated by SDS-PAGE and immunoblotted (IB) with anti-HA or anti-GFP, as indicated. (D) K562 cells were transfected 
with JAM-L  –  HA or double transfected with JAM-L  –  HA and the human     4 subunit. Cells were then untreated (    ) or treated with SDF-1     (100 ng/ml for 
5 min), then treated or not with BS 
3   before cell lysis and Western blot analysis. Numbers next to gel blots indicate molecular mass markers in kD. (E) The 
proportion of dimeric and monomeric forms of JAM-L in D was calculated using ImageJ.     JCB • VOLUME 183 • NUMBER 6 • 2008  1170
by the adjacent cell (  Weber et al., 2007  ). The dimerization motif 
of JAM-A was therefore shown to be required for homophilic 
interaction and function in intercellular junction assembly 
(  Bazzoni et al., 2000  ;   Liu et al., 2000  ;   Mandell et al., 2004  ). 
JAM-L possesses a comparable dimerization motif, which sug-
gests that it may dimerize in a similar way. Accordingly, we show 
here that a dimerization-defective mutant of JAM-L abolishes 
JAM-L ability to form dimers and engage in heterophilic inter-
actions with its counter-receptor CAR. These data provide evi-
dence that cis dimerization of JAM-L is required for heterophilic 
interaction, as the dimerization motif of JAM-L was shown to not 
be directly involved in heterophilic interaction. Indeed, a previous 
study documented that JAM-L binding to CAR was mediated 
by an interaction between the membrane-distal Ig domain of CAR 
and the membrane-proximal Ig domain of JAM-L (  Zen et al., 
2005  ). JAM-L cis dimerization via interaction between both 
membrane-distal Ig domains might either unmask the CAR 
binding site within the membrane-proximal Ig domain of JAM-L 
and/or stabilize the interaction in trans between JAM-L and CAR. 
  How VLA-4 controls JAM-L dimerization and binding to 
CAR is still unclear. Our data indicate that, when present in an 
inactive conformation, VLA-4 is engaged in a complex with 
JAM-L, preventing the formation of JAM-L dimers. Integrin ac-
tivation by Mn 
2+   or a chemokine such as SDF-1   ,  which  is 
known to induce conformational changes within the integrin 
extracellular domains, is accompanied by the dissociation of 
JAM-L  –  VLA-4 complexes and the accumulation of JAM-L di-
mers at the cell surface. It is therefore tempting to speculate that 
a direct interaction between the extracellular domains of JAM-L 
and VLA-4 in its inactive conformation prevents the formation 
of JAM-L dimers. Interestingly, evidence for direct interaction 
between JAM and integrins has already been provided, thus 
strengthening our hypothesis: (1) JAM-A interaction in trans 
with LFA-1 integrin was shown to be mediated by the open ac-
tive I domain in the     L subunit of LFA-1, which binds to the 
membrane-proximal Ig domain of JAM-A on endothelial cells 
(  Fraemohs et al., 2004  ); and (2) VLA-4 can directly bind in trans 
to the distal Ig domain of JAM-B on endothelial cells (  Cunning-
ham et al., 2002  ). However, no stabilization of VLA-4  –  JAM-L 
complexes was found in the presence of the chemical cross-
linker, BS 
3  , which suggests that VLA-4 may not be in close con-
tact with JAM-L. It is therefore possible that VLA-4 might also 
indirectly affect the dimerization state of JAM-L either through 
an interaction with other transmembrane proteins or through an 
interaction with the cortical actin cytoskeleton. Indeed, because 
chemokine-induced integrin activation promotes specifi  c inter-
actions of the      and      cytoplasmic domains of integrins with 
components of the cytoskeleton, VLA-4 activation could con-
tribute to the stabilization of functional JAM-L dimers by facili-
tating its interaction with cytoskeletal regulators. Future structural 
and biochemical studies will aim to identify the precise mecha-
nisms by which VLA-4 controls JAM-L dimerization. 
  In addition, it is interesting to note that SDF-1     treatment 
of K562 cells expressing JAM-L slightly increased the quantity 
of JAM-L dimers and JAM-L  –  mediated adhesion to CAR, al-
though these cells do not express VLA-4. Therefore, we cannot 
exclude the possibility that another integrin may control JAM-L 
of JAM-L in the recruitment to peripheral tissues of the fi  rst ef-
fectors of both innate and adaptative immune responses. 
  Our data suggest that JAM-L promotes leukocyte adhe-
sion to endothelial cells by interacting with CAR. This protein, 
structurally related to the JAMs and best known as a receptor for 
coxsackie B and adenoviruses, is mainly expressed in polarized 
epithelia at the tight junctions (  Cohen et al., 2001  ). Adhesive 
interactions between CAR and JAM-L were shown to facilitate 
the transepithelial migration of neutrophils (  Zen et al., 2005  ). 
However, little is known about the tissue and cellular distribu-
tion of CAR in human vasculature. Future studies will deter-
mine whether JAM-L interaction with endothelial CAR may 
facilitate the fi  rm adhesion or transmigration of specifi  c leuko-
cyte populations at specifi  c sites. In addition, our data suggest 
that CAR may also promote the adhesion of monocytes and 
T lymphocytes through an interaction with another leukocyte 
receptor that remains to be identifi  ed. 
  The most striking result of the present study is the obser-
vation that JAM-L  –  mediated adhesion of leukocytes to endo-
thelial cells is regulated in cis by the activation state of the 
VLA-4 integrin. Until now, evidence has been provided of a 
functional crosstalk between leukocyte adhesion molecules and 
integrins, promoting the controlled activation of specifi  c integ-
rins at defi  ned steps during the leukocyte adhesion cascade: 
E- and   l-  selectin, which support leukocyte rolling, can induce 
an intermediate affi  nity conformation of the integrin LFA-1, al-
lowing it to transiently bind to ICAM-1, and therefore to play a 
role in leukocyte rolling (  Kadono et al., 2002  ;   Chesnutt et al., 
2006  ). CD44-mediated rolling may improve VLA-4 ability to 
support T cell adhesion under fl  ow (  Nandi et al., 2004  ). In addi-
tion, ligation of PECAM-1 on leukocytes can lead to integrin 
activation and increased expression of     6    1   integrin on the sur-
face of transmigrating neutrophils, enabling neutrophil migration 
through the endothelial basement membrane (  Dangerfi  eld et al., 
2002  ). Conversely, our results provide new evidence that the 
activation of leukocyte integrin promotes the adhesive function 
of another leukocyte adhesion molecule: JAM-L. 
  Interestingly, there is now a growing body of literature 
documenting coordinated functions between integrins and JAM 
family members: an interaction in trans between integrins and 
JAM family members can occur during leukocyte diapedesis, 
as described for JAM-A and JAM-B, which engage in trans 
with LFA-1 and VLA-4, respectively ( Cunningham et al., 2002 ; 
  Ostermann et al., 2002  ). In addition, controlled activation in cis 
of endothelial or epithelial integrins by JAMs was described 
during cell migration and growth factor  –  mediated angiogenesis 
(  Mandell et al., 2005  ;   Naik and Naik, 2006  ;   Mandicourt et al., 
2007  ). We demonstrate here that VLA-4 regulates JAM-L func-
tion in cis by controlling its dimerization state. Crystal struc-
tures revealed that JAM-A molecules form homodimers in cis 
via a dimerization motif in their membrane-distal Ig-like do-
main (  Kostrewa et al., 2001  ;   Prota et al., 2003  ). The presence of 
a short linker sequence connecting the two Ig-like domains im-
poses a bent conformation, which is stabilized by hydrogen 
bonding. As a result, dimers emerge from the cell surface in the 
shape of an inverted U, enabling tetramer formation with extra-
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cell line  –  speciﬁ  c programs: T-16 for K562 cells and V-01 for U937 cells. 
Cells were then diluted to 0.5   ×   10 
6   cells/ml in culture medium for 8 or 24 h 
before the experiment. 
  Flow cytometry 
  Cell surface labeling with nonconjugated antibodies (anti-JAM-L and anti-    4) 
was performed by sequential incubation of 5   ×   10 
5   cells with primary anti-
bodies for 30 min at 4  °  C in cold FACS buffer (PBS, 3% FCS, and 0.01% so-
dium azide), followed by incubation of the cells with conjugated secondary 
antibody for 30 min at 4  °  C in cold FACS buffer. Cell surface labeling with 
ﬂ  uorescent-conjugated antibodies was performed by incubation of 5   ×   10 
5   
cells with coupled antibodies for 30 min at 4  °  C in cold FACS buffer. After 
three washes with FACS buffer, cells were ﬁ  xed with 4% PFA and analyzed 
by ﬂ  ow cytometry (FC500 ﬂ  ow cytometer; Beckman Coulter). 
  Binding of leukocytes to recombinant chimeric-Fc proteins 
  Puriﬁ   ed recombinant Fc chimeric proteins were immobilized overnight at 
4  °  C in 48-well (1   μ  g/well) or 96-well plates (0.5   μ  g/well) in 25 mM Tris, pH 
8, buffer supplemented with 150 mM NaCl, 2 mM MgCl  2  , and 2 mM 
CaCl  2  . Wells were then saturated with 1% BSA in PBS for 1 h at room tem-
perature. Before binding assays, freshly isolated leukocytes or cell lines were 
loaded with CMFDA according to the manufacturer instructions. Cells were 
then washed and diluted in the indicated buffers: either RPMI medium, PBS 
buffer without Ca/Mg (PBS    /    ) supplemented with EDTA, or PBS (    /    ) 
buffer supplemented with 0.5 mM Mn 
2+  . Neutrophils or monocytes were 
added to the coated 48-well plates at 5   ×   10 
5   cells per well. K562 cells or 
U937/JAM-L cells were added to the coated 96-well plates at 2   ×   10 
5   cells 
per well. Cells were incubated for 40 min at 37  °  C. After three washes in PBS 
(    /    ) buffer supplemented with EDTA or Mn 
2+   to remove nonadherent cells, 
adherent CMFDA-loaded cells were lysed with water, and ﬂ  uorescence in-
tensity was quantiﬁ  ed using a ﬂ  uorometer (Fusion; PerkinElmer). Where indi-
cated, K562 cells were transfected with vector encoding JAM-L  –  GFP, and the 
number of adherent GFP-positive cells was determined by ﬂ  ow cytometry. 
  Leukocyte adhesion to HBMEC 
  HBMEC were seeded on 48-well plates (10 
5   cells per well) and cultured for 
48 h to reach conﬂ  uence. Leukocytes were loaded with CMFDA, and adhe-
sion to HBMEC was assayed using 2   ×   10 
5   cells per well in PBS (    /    ) buffer 
supplemented with 0.5 mM EDTA, 100 ng/ml SDF-1    , or 0.5 mM Mn 
2+   for 
30 min at 37  °  C. After three washes, adherent cells were lysed with water, and 
ﬂ  uorescence intensity was quantiﬁ  ed using a ﬂ  uorometer (Fusion). Where indi-
cated, K562 cells were transfected with vector encoding JAM-L  –  GFP, and the 
number of adherent GFP positive cells was determined by ﬂ  ow cytometry. Data 
are presented as the mean   ±   SD and were compared by a student  ’  s   t   test. 
  Immunoﬂ  uorescence microscopy 
  13-mm Permanox coverslips were coated with poly-  L  -lysine in PBS buffer for 
30 min at 37  °  C and washed twice with PBS buffer. Freshly isolated T lym-
phocytes were added in RPMI medium for 30 min at 37  °  C (5   ×   10 
5   per 
well). Nonadherent cells were removed, and adherent cells were untreated 
or treated with 100 ng/ml SDF-1     for 10 min at 37  °  C. Cells were ﬁ  xed in 
4% PFA for 10 min and washed three times with PBS buffer. After a 30-min 
treatment with blocking solution (PBS and 3% BSA), cells were stained for 
2 h with the primary antibodies. After three washes with PBS, cells were incu-
bated for 45 min with a mixture of secondary antibodies coupled to cyanin-2 
and cyanin-5, and with rhodamine-phalloidin. Labeled preparations were 
mounted in Mowiol and were analyzed by confocal microscopy (TCS SP2 
AOBS; Leica) with an inverted microscope (DMIRE2; Leica) using a 63  ×   1.4 
NA DIC oil HCX Plan-Apo objective (Leica). Acquisitions were made with a 
LCS (Leica) and FCS (ISS) software at zoom 6. 
  Immunoprecipitations, SDS-PAGE, and Western blotting 
  Leukocytes (5   ×   10 
6   cells) were washed with PBS (    /    ) buffer. Cells were un-
treated or treated with 100 ng/ml SDF-1     for 5 min in PBS (    /    ) buffer. 
When indicated, cells were treated with 2 mM BS 
3   for 40 min at 4  °  C, then in-
cubated in 15 mM Tris, pH 7.5, for 15 min at 4  °  C, according to the manufac-
turer  ’  s instructions, before cell lysis. Cells were then lysed in a digitonin-based 
buffer (1  ×   TBS, 1% digitonin, 5 mM NaF, 2 mM Na  3  VO  4  , 1 mM 4-(2-amino-
ethyl) benzenesulfonyl ﬂ  uoride hydrochloride [AEBSF], 10   μ  g/ml aprotinin, 
10   μ  g/ml leupeptin, and 10   μ  g/ml pepstatin). The insoluble fractions were re-
moved by centrifugation, and the cleared lysates were used for immunopre-
cipitations with speciﬁ  c antibodies for 3 h at 4  °  C. Then, protein G  –  sepharose 
beads (GE Healthcare) were added for 1 h at 4  °  C. Precipitated proteins were 
washed three times, solubilized in Laemmli buffer, and boiled at 100  °  C for 
5 min. Samples were resolved on 7.5% SDS-PAGE gels and transferred to nitro-
cellulose membranes (Schleicher   &   Schuell). After saturation in PBS containing 
3% nonfat dry milk and 0.1% Tween 20 (blocking buffer) for 30 min, membranes 
function to a lesser extent. In light of our present fi  ndings, it will 
now be of particular interest to address whether VLA-4 or other 
integrins control the functional activity of other adhesion mole-
cules, and, in particular, whether VLA-4 may also control JAM-C 
function, as the interaction in trans between leukocyte VLA-4 
and endothelial JAM-B cannot be observed in the absence of 
leukocyte JAM-C expression (  Cunningham et al., 2002  ). 
  In conclusion, by demonstrating an original regulation in 
cis of the leukocyte adhesion molecule JAM-L function by the 
integrin VLA-4, our results highlight a new degree of complexity 
in the post-adhesion events that strengthen leukocyte attachment 
to the endothelium. Although a network of adhesion molecules 
with overlapping functions mediate the capture, rolling, and fi  rm 
adhesion of leukocytes to the vascular endothelium, this study 
adds a novel twist to this adhesion cascade. 
  Materials and methods 
  Antibodies, reagents, and recombinant chimeric Fc-proteins 
  The anti  –  human JAM-L (AMICA) antibody was obtained from R  &  D Systems; 
anti  –  integrin     4 (clone P4C2) and     1 (clone P5D2) were obtained from Mil-
lipore; anti-    2 activation epitope antibody (clone MEM-148) was obtained 
from AbD Serotec; anti  –  integrin     1 activation epitope antibody (clone 
9EG7), R-phycoerythrin  –  conjugated anti-    4    7 antibody, and ﬂ  uorescent-
conjugated anti-CD4, anti-CD8, anti-CD45RO, anti-CD45RA, anti  –  cutaneous 
leukocyte antigen (CLA), anti-CCR7, anti-CD25, and anti  –  CC-chemokine recep-
tor 4 (CCR4) were obtained from BD; anti-CD71 (clone DF1513) was ob-
tained from Santa Cruz Biotechnology, Inc.; anti-HA (clone 12CA5), 
anti-GFP, and VSV-g epitope tag (clone P5D4) antibodies were obtained from 
Roche; ﬂ  uorescent-conjugated secondary antibodies, peroxidase-conjugated 
secondary antibodies, and ECL reagents were obtained from Jackson Immuno-
Research Laboratories; Alexa Fluor 488  –  conjugated Phalloidin and the ﬂ  uor-
escent cell tracker 5-chloromethylﬂ   uorescein diacetate (CMFDA) were 
obtained from Invitrogen; human recombinant SDF-1     was obtained from 
Abcys; digitonin and poly-  L  -Lysine solution were obtained from Sigma-
Aldrich; recombinant Fc-chimeric proteins were all purchased from R  &  D 
Systems; and BS 
3   was obtained from Thermo Fisher Scientiﬁ  c. 
  Cells and culture conditions 
  HBMECs, provided by B.B. Weksler (Weill Medical College of Cornell Uni-
versity, New York, NY;   Schweitzer et al., 1997  ), and a U937 human mono-
cytic cell line stably transfected with the pMT-JAML-HA expression vector 
encoding full-length JAM-L protein fused with a HA epitope (U937/JAM-L) 
were grown as described previously (  Hoffmann et al., 2001  ;   Moog-Lutz 
et al., 2003  ). JAM-L protein expression was induced by addition of 0.1 mM of 
ZnSO  4   for 18 h in RPMI culture medium. Human K562 cells from American 
Type Culture Collection were grown in RPMI-1640 medium supplemented with 
10% heat-inactivated FCS and 10 mM Hepes. Human leukocytes from peri  ph-
eral blood of healthy volunteers were isolated by centrifugation through a 
Ficoll-Paque Plus (GE Healthcare) gradient. Granulocytes were enriched using 
standard protocols (  Doulet et al., 2006  ); T lymphocytes and monocytes 
were isolated by magnetic negative cell sorting using a Dynal T Cell Nega-
tive Isolation kit and a Dynal Monocyte Negative Isolation kit (Invitrogen). 
Human CD34 
+   hematopoietic stem cells were provided by S. Fichelson 
(Institut Cochin, Paris, France) and directly used for FACS analysis. 
  cDNA constructs and cell transfections 
  Vectors encoding JAM-L tagged with the HA epitope at its C terminus 
(p513-JAM-L-HA vector) and the p513-JAM-L-K54D-HA vector with a muta-
tion in the putative dimerization domain have been described previously 
(  Moog-Lutz et al., 2003  ). The sequence encoding JAM-L was subcloned 
into the pEGFP-N3 vector (Clontech Laboratories, Inc.). The vector encoding 
the head domain of talin coupled to GFP has been described previously 
(  Tadokoro et al., 2003  ). The vector encoding GFP-tagged human ICAM-1 was 
provided by F. Sanchez-Madrid (Hospital Universitario de La Princesa, Madrid, 
Spain). Vectors encoding human nontagged and GFP-tagged     4 integrin 
were provided by M.J. Humphries (University of Manchester, Manchester, 
England, UK). Cells were transfected using the Nucleofector system (Amaxa 
Biosystems). 5   ×   10 
6   cells were suspended in 100   μ  l of Nucleofector solu-
tion mix with 2  –  5   μ  g of plasmids and subjected to electroporation using the JCB • VOLUME 183 • NUMBER 6 • 2008  1172
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